Challenges in Allogeneic Mesenchymal Stem Cell-Mediated Cardiac Repair

Trends in Cardiovascular Medicine

Volumn 20, Issue 8, 2010, Pages 263-268

  Dhingra, Sanjiv ^a   Huang, Xi Ping ^a   Li, Ren Ke ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE ANTIGEN; NEUTRALIZING ANTIBODY; NITRIC OXIDE; PROSTAGLANDIN E2; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE HEART INFARCTION; ANTIGEN EXPRESSION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL REGENERATION; CLINICAL EFFECTIVENESS; DNA MODIFICATION; GRAFT REJECTION; HEART FUNCTION; HEART INJURY; HEART MUSCLE; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SURVIVAL; T LYMPHOCYTE; TISSUE REPAIR;

CELL DIFFERENTIATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; MYOCARDIUM; TRANSPLANTATION, HOMOLOGOUS;

EID: 84863414540     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2011.12.002     Document Type: Review

References (47)

1. Abdullah Z., Saric T., Kashkar H., et al. Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J Immunol 2007, 178:3390-3399.
2. Amado L.C., Saliaris A.P., Schuleri K.H., et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005, 102:11474-11479.
3. 2 in human mesenchymal stem cells. J Cell Physiol 2004, 200:400-406.
4. Asseman C., Powrie F. Interleukin 10 is a growth factor for a population of regulatory T cells. Gut 1998, 42:157-158.
5. Assmus B., Honold J., Schachinger V., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006, 355:1222-1232.
6. Bainbridge D.R., Ellis S.A., Sargent I.L. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000, 48:17-26.
7. Beyth S., Borovsky Z., Mevorach D., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105:2214-2219.
8. Caspi O., Gepstein L. Regenerating the heart using human embryonic stem cells: From cell to bedside. Isr Med Assoc J 2006, 8:208-214.
9. Chen X., McClurg A., Zhou G.Q., et al. Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells 2007, 25:364-370.
10. Di N.M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
11. Dib N., Menasche P., Bartunek J.J., et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: A report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv 2010, 3:265-275.
12. Durkin E.T., Jones K.A., Elnaggar D., Shaaban A.F. Donor major histocompatibility complex class I expression determines the outcome of prenatal transplantation. J Pediatr Surg 2008, 43:1142-1147.
13. Fazel S., Tang G.H., Angoulvant D., et al. Current status of cellular therapy for ischemic heart disease. Ann Thorac Surg 2005, 79:S2238-S2247.
14. Figueiredo C., Horn P.A., Blasczyk R., Seltsam A. Regulating MHC expression for cellular therapeutics. Transfusion 2007, 47:18-27.
15. Frumento G., Rotondo R., Tonetti M., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002, 196:459-468.
16. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001, 2:917-924.
17. Griffith T.S., Yu X., Herndon J.M., et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996, 5:7-16.
18. Haga K., Lemp N.A., Logg C.R., et al. Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: Averting cytotoxicity by alloreactive T lymphocytes. Transplant Proc 2006, 38:3184-3188.
19. Hare J.M., Traverse J.H., Henry T.D., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
20. Harizi H., Juzan M., Pitard V., et al. Cyclooxygenase-2-issued prostaglandin E(2) enhances the production of endogenous IL-10, which downregulates dendritic cell functions. J Immunol 2002, 168:2255-2263.
21. Huang X.P., Sun Z., Miyagi Y., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010, 122:2419-2429.
22. Ito T., Meyer K.C., Ito N., Paus R. Immune Privilege and the Skin. Dermatologic Immunity 2008, 27-52. Karger, Basel. B.J. Nickoloff, F.O. Nestle (Eds.).
23. Kehat I., Khimovich L., Caspi O., et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004, 22:1282-1289.
24. Kim D.H., Yoo K.H., Choi K.S., et al. Gene expression profile of cytokine and growth factor during differentiation of bone marrow-derived mesenchymal stem cell. Cytokine 2005, 31:119-126.
25. Kinkaid H.Y., Huang X.P., Li R.K., Weisel R.D. What's new in cardiac cell therapy?. Allogeneic bone marrow stromal cells as "universal donor cells". J Card Surg 2010, 25:359-366.
26. 2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sites. BMC Immunol 2003, 4:7.
27. Lipinski M.J., Biondi-Zoccai G.G., Abbate A., et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007, 50:1761-1767.
28. Liu C.T., Yang Y.J., Yin F., et al. The immunobiological development of human bone marrow mesenchymal stem cells in the course of neuronal differentiation. Cell Immunol 2006, 244:19-32.
29. 2. J Neuroimmunol 2011, 233:106-111.
30. Nemeth K., Leelahavanichkul A., Yuen P.S., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
31. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
32. Pearl J.I., Lee A.S., Leveson-Gower D.B., et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011, 8:309-317.
33. Poncelet A.J., Vercruysse J., Saliez A., Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007, 83:783-790.
34. Rando T.A. Stem cells, ageing and the quest for immortality. Nature 2006, 441:1080-1086.
35. Rasmusson I., Ringden O., Sundberg B., Le B.K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
36. Rauscher F.M., Goldschmidt-Clermont P.J., Davis B.H., et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003, 108:457-463.
37. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
38. Rodgers J.R., Cook R.G. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 2005, 5:459-471.
39. Rouas-Freiss N., Goncalves R.M., Menier C., et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997, 94:11520-11525.
40. Sato K., Ozaki K., Oh I., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
41. Schachinger V., Erbs S., Elsasser A., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
42. Tomita S., Li R.-K., Weisel R.D., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999, 100:247-256.
43. Tomita S., Mickle D.A.G., Weisel R.D., et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg 2002, 123:1132-11340.
44. Wekerle T., Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999, 68:459-467.
45. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
46. 2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 2010, 316:3109-3123.
47. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.